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A Molecular Mechanism 
for Abnormal Prion Protein 
Accumulation
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Abstract
A fundamental event in the pathogenesis of prion disease is the conversion 
of cellular prion protein into an abnormally folded isoform (PrPSc), which is the 
infectious causative agent of disease. With progression of disease, PrPSc is replicated 
and excessively accumulated in most cases. However, the molecular mechanism for 
excessive accumulation of PrPSc is not well understood. Recently, Sortilin, a mem-
ber of the VPS10P domain receptor family, has been identified as a sorting receptor 
that directs prion protein (PrP) to the lysosomal degradation pathway. Moreover, it 
has been shown that prion infection impairs Sortilin function, resulting in delayed 
PrPSc degradation. In this chapter, we explain the mechanisms for PrP trafficking 
into the lysosomal degradation pathway mediated by Sortilin and overaccumulation 
of PrPSc caused by Sortilin dysfunction.
Keywords: PrPSc, PrPSc accumulation, PrPSc degradation, Sortilin, sorting, VPS10P 
domain, sorting receptor, VPS10P domain receptor
1. Introduction
Prion diseases are a group of fatal neurodegenerative disorders that are caused 
by the transmissible misfolded isoform (PrPSc) of the cellular prion (PrPC) [1], 
including Creutzfeldt-Jakob disease of humans, bovine spongiform encephalopathy, 
and scrapie of sheep. PrPSc is a β-sheet rich conformer of PrPC and is partially resis-
tant to protease. With progression of prion disease, PrPSc is replicated and accumu-
lated in the brain, and neuronal dysfunction and death occur. Previous studies have 
shown that PrP-null mice neither develop the disease nor accumulate PrPSc even 
after prions are inoculated into their brains [2, 3]. This indicates that replication 
and accumulation of PrPSc are closely related to the pathogenesis of prion disease. 
Therefore, elucidation of the mechanisms of PrPSc degradation and accumulation 
is critical for understanding the pathogenic mechanism of prion disease and for 
developing therapeutic agents.
PrPSc usually accumulates excessively over PrPC in cultured cells and mouse 
brains (Figure 1). This strongly indicates that PrPSc is protected against its pro-
teolytic degradation. Actually, several studies have reported that the proteolytic 
systems (e.g., lysosomal degradation and ubiquitin-proteasomal degradation 
systems) are inhibited by prion infection [4–7], and PrPSc is found at the cell sur-
face and in endosomal/lysosomal compartments [8–10]. Moreover, when PrPSc was 
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fractionated by detergent-based biochemical fractionation, most of the PrPSc was 
detected in detergent-resistant membrane (DRM) fractions [11], suggesting that 
PrPSc mainly exists in membrane bound form and PrPSc is degraded preferentially 
in lysosomes, but not by cytosolic proteasomes. PrPSc to be degraded in lysosomes 
might be preferentially selected and directed into the lysosomal degradation 
pathway by dedicated membrane trafficking machinery. Therefore, knowledge of 
the mechanism that sorts PrP into late endosomal/lysosomal compartments should 
be important for understanding the accumulation of PrPSc.
2. PrPSc accumulation
Figure 1A shows the expression of total PrP and PrPSc in uninfected and prion-
infected mouse brains. In this figure, we can easily recognize that the total amount 
of PrP in infected mouse brains is larger than in uninfected mouse brains. In 
cultured cells, such excessive expression of total PrP in infected cells was also con-
firmed (Figure 1B). These results indicate that the amount of PrPSc in infected cells 
is larger than PrPC in uninfected cells, and that PrPSc is protected against proteolytic 
degradation.
Why is PrPSc protected from proteolysis and over-accumulated? One possible 
reason is the protease resistance of PrPSc that is attributed to its β-rich structure at the 
C-terminal region. If such protease resistance mainly affected the inhibition of PrPSc 
degradation, most of the PrPSc could be found in the lysosome, which contains various 
kinds of hydrolytic enzymes and is a major compartment responsible for the diges-
tion of macromolecules such as proteins. The majority of PrPSc is actually observed 
intracellularly, whereas PrPC mainly localizes to the cell surface (Figure 2A). However, 
detailed analyses of its intracellular distribution show that PrPSc is widely distributed 
in posttrans Golgi network (TGN) compartments [8–10] (Figure 2B). From these 
Figure 1. 
PrP expression in mice brain and N2a cells. (A) Total PrP and PrPSc were compared between RML prion 
infected mouse brains at terminal stage and age matched uninfected mice brain by western blotting. (B) N2a 
cells were treated with uninfected or 22 L-prion infected mice brain homogenate. At 30 dpi, total PrP and PrPSc 
were detected by western blotting. Blots were probed with anti-PrP antibody (6D11) and anti-β-actin antibody.
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observations, it seems that impairment of PrPSc trafficking into lysosomes as well as its 
protease-resistance causes inhibition of degradation and over-accumulation of PrPSc.
3. Sortilin and other VPS10P domain receptors
PrP would have to move by transport vesicles in post-TGN compartments, 
including TGN, endosomes, lysosomes, and the plasma membrane. Then, in this 
transport network, the PrP to be degraded could be sorted into transport carriers 
bound for late endosomal/lysosomal compartments. For this purpose, a sorting 
receptor might be useful and required because it can select and concentrate a 
target cargo protein into transport carriers and promote transport carrier forma-
tion. In our recent study, Sortilin has been identified as a sorting receptor that 
directs PrP into late endosomal/lysosomal compartments. Sortilin is a member 
of the VPS10P domain receptor family, which is comprised of five members 
(Sortilin, SorCS1, SorCS2, SorCS3, and SorLA). In this section, briefly, we 
describe Sortilin and other VPS10P receptors and their implications for neurode-
generative diseases.
Figure 2. 
PrPSc is widely distributed in post-Golgi compartments. (A) PrPC (green, uninfected cells) and PrPSc (green, 
infected cells) were visualized by immunofluorescence staining with mouse monoclonal anti-PrP antibody 
(SAF83) and anti-PrPSc antibody (132), respectively. (B) PrPSc indicated organelle markers in prion infected 
cells were doubly stained with anti-PrPSc antibody (132) and anti-transferrin receptor, Rab11, Rab5, Rab9 and 
LAMP1 antibody, respectively. DAPI was used for nuclear stain (blue).
Prions - Some Physiological and Pathophysiological Aspects
4
VPS10P-domain receptors are multiligand type-I transmembrane proteins. They 
contain five members, Sortilin, SorLA, SorCS1, SorCS2, and SorCS3, and deliver 
a number of target cargo proteins to their destinations, interacting with them via 
VPS10P domains on the luminal/extracellular N-terminus (Figure 3). The whole 
luminal/extracellular region in Sortilin is composed of a simple VPS10P domain, 
but other receptors have additional modules (Figure 3).
VPS10P-domain receptors are expressed in the brain and are involved in neuro-
nal function and viability [12, 13]. Sortilin binds to progranulin and mediates endo-
cytosis and delivery of progranulin into lysosomes [14], and rare nonsynonymous 
variants in SORT1 increase the risk for frontotemporal lobar degeneration [15]. 
Sortilin also mediates trafficking of neuronal degeneration causative and related 
proteins. Sortilin has been identified as an amyloid precursor protein (APP) inter-
action partner and promotes α-cleavage of APP [16]. In addition, Sortilin interacts 
with BACE1, β-site APP cleavage enzyme 1, and mediates its retrograde trafficking 
from the plasma membrane to TGN via early endosomes [17]. It has been suggested 
that Sortilin is potentially associated with Parkinson’s disease [18]. Moreover, 
recently, it has been reported that Sortilin is involved in tau prion replication [19].
As for other VPS10P receptors, it has been reported that SorLA is associated with 
sporadic and late-onset Alzheimer’s disease (AD) [5, 20]. SorLA directs APP into 
the recycling pathway and protects APP from β-cleavage resulting in Aβ generation 
[5, 21, 22]. On the other hand, loss of SorLA shifts the traffic flow of APP to the late 
endosomal pathway and facilitates β-cleavage of APP and Aβ-generation [5, 21, 22]. 
In addition, a meta-analysis indicated that multiple SorLA variants are associated 
with the risk of Alzheimer’s disease [23]. SorCS1 is also involved in APP transport and 
Aβ-generation and is identified as a risk factor for Alzheimer’s disease [24, 25]. Variants 
of SorCS2 and SorCS3 are also associated with the risk of Alzheimer’s disease [24, 
25]. Although a number of studies have indicated that VPS10P-domain receptors are 
Figure 3. 
VPS10P domain receptors. VPS10P-domain receptors are multiligand type-I transmembrane proteins. They 
contain five members, Sortilin, SorLA, SorCS1, SorCS2 and SorCS3. The extracellular/luminal region of 
VPS10P receptors contains VPS10P domain and additional domains. The intracellular domain of VPS10P 
receptors contains motifs for interaction with adaptor proteins. The propeptide at N-terminal region is cleaved 
by furin in the TGN.
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implicated in neurodegenerative diseases and their impairment could be a risk factor 
for diseases, the relation between VPS10P receptors and prion disease is not known.
4. Role of Sortilin in PrP trafficking
Sortilin has been identified as a novel PrP-binding protein and is colocalized 
with PrPC both at the cell surface and intracellular compartments [11]. In Sortilin-
knockdown (Sortilin-KD) uninfected cells, most of the PrPC is localized at the cell 
surface, and PrPC expression is increased. In addition, a PrPC uptake experiment, in 
which cell surface PrPC was labeled with anti-PrP antibody and internalized labeled 
PrPC was measured after incubation, demonstrated that PrPC internalization was 
weakened by Sortilin-KD [11]. These results indicate that Sortilin acts as a cell 
surface receptor for PrPC endocytosis.
PrPC was also colocalized with Sortilin intracellularly [11]. This made us recollect 
that Sortilin could function intracellularly as a sorting receptor for PrP trafficking. 
When the internalized labeled PrPC was costained for either Rab9 (a late endosomal 
marker) or Rab11 (a recycling endosomal marker) by indirect immunofluorescence, 
the internalized PrPC distributed to both late and recycling endosomes in control cells, 
whereas, in Sortilin-depleted cells, it failed to localize to late endosomes, and most of 
the internalized PrPC is localized to recycling endosomes [11]. These observations indi-
cate that Sortilin is also required for sorting of PrPC into late endosomes to degrade it.
Moreover, when wild type (wt) and Sortilin-knockout (ΔSort) cells were treated 
with NH4Cl, which increases lysosomal pH and inhibits proteolytic enzymes in 
lysosomes, PrPC was effectively accumulated in wt but not in ΔSort cells [11], and 
PrPC colocalization with LAMP1, a lysosomal marker, in NH4Cl-treated ΔSort cells 
was significantly lower than NH4Cl-treated wt cells [11]. These results suggest that 
ΔSort cells failed to transport PrPC properly into lysosomes.
Altogether, it could be concluded that Sortilin functions as a cell surface receptor 
for PrPC internalization and a sorting receptor to direct PrPC to lysosomes via late 
endosomes (Figure 4). We would be able to extend such a role of Sortilin in PrPC 
trafficking to PrPSc because Sortilin directly interacted with PrPC through its highly 
flexible N-terminal domain and anti-Sortilin antibody coprecipitated both PrPC and 
PrPSc. In practical terms, Sortilin is implicated in PrPSc degradation.
The inhibition of Sortilin inhibited PrPC internalization by ~20% in the PrPC 
uptake assay [11]. This result raises a question. Why is PrPC endocytosis inhibited 
partially even when Sortilin function is almost or completely abolished [11]? There 
are suggestive findings to answer this question. We examined the PrP distribution 
in uninfected wt cells and in uninfected ΔSort cells by detergent-based biochemical 
fractionation. Sixty three percent of PrPC in wt cells was detected in detergent resis-
tant membrane (DRM) fractions, generally recognized as raft fractions, but thirty-
seven percent of PrPC was also found in detergent soluble (nonraft) fractions [11]. 
Sortilin deficiency changed the PrPC distribution, and PrPC in nonraft fractions was 
reduced to ~15% in ΔSort cells [11]. At present, it is thought that both lipid raft- and 
clathrin-mediated endocytosis execute PrPC internalization [13, 26]. Sortilin was 
mostly isolated in nonraft fractions [11]. It has been reported that the cytoplasmic 
tail of Sortilin can interact with clathrin-associated adaptor protein complex, AP-2, 
at the plasma membrane and facilitate clathrin-mediated endocytosis [13, 27, 28]. 
We showed that the recombinant PrP devoid of its N-terminal domain (residues 
23–88) (PrPΔ23–88) did not bind to Sortilin. Additionally, internalization and 
lysosomal degradation of PrPΔ23–88 were inhibited, and it accumulated at the 
cell surface [11]. These results are in good agreement with a previous report: the 
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N-terminal domain (residues 23–107) of PrPC is sufficient for its endocytosis medi-
ated by clathrin [29]. It is therefore inferred that Sortilin internalizes PrPC from 
nonraft domains at the cell surface by clathrin-coated vesicles. Moreover, it has been 
shown that the expression of total PrPC was not changed even when the flotillin-1–
mediated lipid raft-dependent endocytosis of PrPC was inhibited by the knockdown 
of flotillin-1 [30]. Their and our results suggest that Sortilin-mediated endocytosis 
directs PrPC into the late endosomal/lysosomal degradation pathway, whereas PrPC 
that is internalized from the lipid raft domain in a Sortilin-independent manner 
largely enters the recycling pathway (Figure 4).
5. Dysfunction of Sortilin by prion infection
Sortilin expression also affects PrPSc levels. Sortilin-KD increased PrPSc in 
prion infected cells, similarly to PrPC in uninfected cells [11]. On the contrary, 
overexpression of Sortilin in infected cells reduced PrPSc [11]. Furthermore, when 
we investigated PrPSc accumulation in Sort1+/+ and Sort1−/− mouse brains after intra-
cerebral prion inoculation, PrPSc levels in Sort1−/− mouse brains were significantly 
higher than in Sort1+/+ mouse brains at the early stages of disease (at 45, 60, 90 dpi) 
[11], suggesting an inhibition of PrPSc degradation. Namely, dysfunction of Sortilin 
causes excessive accumulation. If so, does prion infection inhibit Sortilin function? 
Notably, Sortilin in infected cells was ~50% lower than in uninfected cells [11]. 
Moreover, in infected mouse brains at terminal stage, Sortilin also fell to ~45% as 
compared with age-matched uninfected mice [11]. These observations suggested 
that prion infection downregulated Sortilin expression. To confirm this, uninfected 
cells were treated with RML prion-infected mouse brain homogenate, and Sortilin 
and PrPSc in individual cells were visualized by double immunofluorescence stain-
ing at 9 dpi (Figure 5). In cells displaying bright green signals derived from PrPSc, 
little Sortilin (red) was detected, whereas the bright red fluorescence of Sortilin was 
observed in the others; that is, Sortilin expression was reduced by prion infection.
Figure 4. 
Role of Sortilin in PrP-trafficking. Sortilin internalizes PrP from nonraft domain and direct into late 
endosomal/lysosomal degradation pathway. PrP internalized from lipid raft domain in Sortilin-independent 
manner would be largely recycled into cell surface. PrP might be also internalized from nonraft domain in 
Sortilin-independent manner. Red arrows indicate Sortilin mediated PrP-trafficking pathway. Blue line is 
lipid raft domain. EE: Early endosome, LE: Late endosomes, RE: Recycling endosomes, Lys: Lysosomes, PM: 
Plasma membrane.
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To clarify why Sortilin is reduced by prion infection, we examined mRNA 
transcript levels by RT-PCR. There was little difference in Sortilin mRNA abun-
dance between uninfected and infected cells. This suggested that the degradation of 
Sortilin was facilitated in prion infected cells. Hence, we treated cells with inhibi-
tors of proteolytic degradation. The expression of Sortilin was almost the same in 
both untreated and MG132-treated cells but increased in NH4Cl-treated cells [11]. In 
particular, Sortilin expression was dramatically improved in NH4Cl-treated prion-
infected cells, and another lysosomal inhibitor, concanamycin A, also improved 
Sortilin expression in infected cells [11], suggesting that Sortilin is over-degraded in 
prion-infected cells in lysosomes.
6. Conclusions
Sortilin has been identified as a novel PrP-binding protein and functions as 
a sorting receptor to direct PrP into late endosomal/lysosomal compartments. 
Figure 5. 
Prion infection reduces Sortilin expression. Immunofluorescence staining of Sortilin (red) and PrPSc (green) 
9 days after infection of uninfected cells with RML prions. Four horizontal serial images at 1 μm interval were 
collected, and orthogonally projected image was created. DAPI was used for nuclear stain (blue). Yellow arrow 
indicates PrPSc-positive cell.
Figure 6. 
Possible mechanism for PrPSc over-accumulation by prion infection. (I) the entry of Sortilin into the lysosomal 
degradation pathway is facilitated (green arrow) by prion infection (yellow arrow), (II) Sortilin is over-
degraded in lysosomes, (III) trafficking of PrPSc to late endosomal/lysosomal compartments is restricted (red 
broken arrow), and (IV) PrPSc is protected against its degradation in lysosomes and is excessively accumulated. 
Red arrows indicate Sortilin-mediated PrP-trafficking pathway and blue arrows indicate other PrP-trafficking 
pathways. EE: Early endosomes, LE: Late endosomes, RE: Recycling endosomes, Lys: Lysosomes, PM: Plasma 
membrane.
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Dysfunction of Sortilin induces delayed degradation and excessive accumulation 
of PrP. Notably, prion infection downregulated Sortilin expression by facilitating 
Sortilin degradation in lysosomes. Finally, we summarize a possible mechanism of 
excessive accumulation of PrPSc during prion infection (Figure 6): (I) the entry of 
Sortilin into the lysosomal degradation pathway is facilitated by prion infection, 
(II) Sortilin is over-degraded in lysosomes, (III) trafficking of PrPSc to late endo-
somal/lysosomal compartments is restricted, and (IV) PrPSc is protected against its 
degradation in lysosomes and is excessively accumulated. However, it still remains 
unclear how prion infection facilitates Sortilin degradation in lysosomes.
Acknowledgements
This work was supported by the following: Pilot Research Support Program 
in Tokushima University received by KU; Naito Foundation received by KU; JSPS 
KAKENHI grant (grant No. 26460557, received by KU; MEXT KAKENHI grant 
(grant No, 17H05702, received by KU; JSPS KAKENHI grant (grant No. 26293212, 
received by SS; MEXT KAKENHI grant (grant No, 15H01560 and 17H05701, 
received by SS; and Practical Research Project for Rare/Intractable Diseases of the 
Japan Agency for Medical Research and Development (AMED) received by SS.
Conflict of interest
The authors have declared that no competing interests exist.
9A Molecular Mechanism for Abnormal Prion Protein Accumulation
References
[1] Prusiner SB. Prions. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
1998;95(23):13363-13383
[2] Büeler H, Aguzzi A, Sailer A, 
Greiner RA, Autenried P, Aguet 
M, Weissmann C. Mice devoid of 
PrP are resistant to scrapie. Cell. 
1993;73(7):1339-1347
[3] Sakaguchi S, Katamine S, 
Shigematsu K, Nakatani A, Moriuchi 
R, Nishida N, Kurokawa K, Nakaoke 
R, Sato H, Jishage K. Accumulation 
of proteinase K-resistant prion 
protein (PrP) is restricted by the 
expression level of normal PrP in mice 
inoculated with a mouse-adapted 
strain of the Creutzfeldt-Jakob 
disease agent. Journal of Virology. 
1995;69(12):7586-7592
[4] Kristiansen M, Deriziotis P, 
Dimcheff DE, Jackson GS, Ovaa H, 
Naumann H, Clarke AR, van Leeuwen 
FWB, Menendez-Benito V, Dantuma 
NP, Portis JL, Collinge J, Tabrizi SJ. 
Disease-associated prion protein 
oligomers inhibit the 26S proteasome. 
Molecular Cell. 2007;26(2):175-188
[5] Rogaeva E, Meng Y, Lee JH, Gu 
Y, Kawarai T, Zou F, Katayama T, 
Baldwin CT, Cheng R, Hasegawa 
H, Chen F, Shibata N, Lunetta KL, 
Pardossi-Piquard R, Bohm C, Wakutani 
Y, Adrienne Cupples L, Cuenco KT, 
Green RC, Pinessi L, Rainero I, Sorbi 
S, Bruni A, Duara R, Graff-Radford 
N, Petersen R, Dickson D, Der SD, 
Fraser PE, Schmitt-Ulms G, Younkin S, 
Mayeux R, Farrer LA, St George-Hyslop 
P. The neuronal sortilin-related receptor 
SORL1 is genetically associated with 
Alzheimer’s disease. Nature Genetics. 
2007;39(2):168-177
[6] Andre R, Tabrizi SJ. Misfolded PrP 
and a novel mechanism of proteasome 
inhibition. Prion. 2012;6(1):32-36
[7] Shim SY, Karri S, Law S, Schatzl 
HM, Gilch S. Prion infection impairs 
lysosomal degradation capacity by 
interfering with rab7 membrane 
attachment in neuronal cells. Scientific 
Reports. 2016;6:21658
[8] Uchiyama K, Muramatsu N, Yano 
M, Usui T, Miyata H, Sakaguchi S. 
Prions disturb post-Golgi trafficking 
of membrane proteins. Nature 
Communications. 2013;4:1846
[9] Yamasaki T, Suzuki A, Shimizu 
T, Watarai M, Hasebe R, Horiuchi 
M. Characterization of intracellular 
localization of PrP Sc in prion-infected 
cells using a mAb that recognizes the 
region consisting of aa 119-127 of mouse 
PrP. The Journal of General Virology. 
2012;93(3):668-680
[10] Veith NM, Plattner H, Stuermer 
CAO, Schulz-Schaeffer WJ, Bürkle A. 
Immunolocalisation of PrPSc in scrapie-
infected N2a mouse neuroblastoma 
cells by light and electron microscopy. 
European Journal of Cell Biology. 
2009;88(1):45-63
[11] Uchiyama K, Tomita M, Yano M, 
Chida J, Hara H, Das NR, Nykjaer A, 
Sakaguchi S. Prions amplify through 
degradation of the VPS10P sorting 
receptor sortilin. PLoS Pathogens. 
2017;13(6):e1006470
[12] Nykjaer A, Lee R, Teng KK, Jansen 
P. Sortilin is essential for proNGF- 
induced neuronal cell death. Nature. 
2004;427:15-20
[13] Nykjaer A, Willnow TE. Sortilin: A 
receptor to regulate neuronal viability 
and function. Trends in Neurosciences. 
2012;35(4):261-270
[14] Hu F, Padukkavidana T, Vagter CB, 
Brady OA, Zheng Y, Mackenzie IR, 
Feldman HH, Nykjaer A, Strittmatter 
SM. Sortilin-mediated endocytosis 
DOI: http://dx.doi.org/10.5772/intechopen.78951
Prions - Some Physiological and Pathophysiological Aspects
10
determines levels of the frontotemporal 
dementia protein, progranulin. Neuron. 
2010;68(4):654-667
[15] Philtjens S, Van Mossevelde S, 
van der Zee J, Wauters E, Dillen L, 
Vandenbulcke M, Vandenberghe 
R, Ivanoiu A, Sieben A, Willems C, 
Benussi L, Ghidoni R, Binetti G, 
Borroni B, Padovani A, Pastor P, Diez-
Fairen M, Aguilar M, de Mendonça A, 
Miltenberger-Miltényi G, Hernández 
I, Boada M, Ruiz A, Nacmias B, Sorbi 
S, Almeida MR, Santana I, Clarimón 
J, Lleó A, Frisoni GB, Sanchez-Valle 
R, Lladó A, Gómez-Tortosa E, Gelpi 
E, Van den Broeck M, Peeters K, Cras 
P, De Deyn PP, Engelborghs S, Cruts 
M, Van Broeckhoven C, BELNEU 
Consortium, and EU EOD Consortium. 
Rare nonsynonymous variants in SORT1 
are associated with increased risk for 
frontotemporal dementia. Neurobiology 
of Aging. 2018;66:181.e3-181.e10
[16] Gustafsen C, Glerup S, Pallesen 
LT, Olsen D, Andersen OM, Nykjaer 
A, Madsen P, Petersen CM. Sortilin 
and SorLA display distinct roles in 
processing and trafficking of amyloid 
precursor protein. The Journal of 
Neuroscience. 2013;33(1):64-71
[17] Finan GM, Okada H, Kim 
T-W. BACE1 retrograde trafficking 
is uniquely regulated by the 
cytoplasmic domain of sortilin. The 
Journal of Biological Chemistry. 
2011;286(14):12602-12616
[18] Dhungel N, Eleuteri S, Li L, Kramer 
NJ, Chartron JW, Spencer B, Kosberg 
K, Fields JA, Stafa K, Adame A, Lashuel 
H, Frydman J, Shen K, Masliah E, 
Gitler AD. Parkinson’s disease genes 
VPS35 and EIF4G1 interact genetically 
and converge on α-synuclein. Neuron. 
2015;85(1):76-87
[19] Johnson NR, Condello C, Guan S, 
Oehler A, Becker J, Gavidia M, Carlson 
GA, Giles K, Prusiner SB. Evidence 
for sortilin modulating regional 
accumulation of human tau prions 
in transgenic mice. Proceedings of 
the National Academy of Sciences. 
2017;114(51):E11029-E11036
[20] Dodson SE, Gearing M, Lippa CF, 
Montine TJ, Levey AI, Lah JJ. LR11/
SorLA expression is reduced in 
sporadic Alzheimer disease but not 
in familial Alzheimer disease. Journal 
of Neuropathology and Experimental 
Neurology. 2006;65(9):866-872
[21] Dodson SE, Andersen OM, 
Karmali V, Fritz JJ, Cheng D, Peng J, 
Levey AI, Willnow TE, Lah JJ, Disease 
N. Loss of LR11/SORLA enhances 
early pathology in a mouse model of 
amyloidosis: Evidence for a proximal 
role in Alzheimer’s disease. Journal of 
Neurobiology. 2009;28(48):12877-12886
[22] Andersen OM, Reiche J, Schmidt V, 
Gotthardt M, Spoelgen R, Behlke J, von 
Arnim CAF, Breiderhoff T, Jansen P, 
Wu X, Bales KR, Cappai R, Masters CL, 
Gliemann J, Mufson EJ, Hyman BT, Paul 
SM, Nykjaer A, Willnow TE. Neuronal 
sorting protein-related receptor sorLA/
LR11 regulates processing of the 
amyloid precursor protein. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2005;102(38):13461-13466
[23] Reitz C, Cheng R, Rogaeva E, 
Lee JH, Tokuhiro S, Zou F, Bettens K, 
Sleegers K, Tan EK, Kimura R, Shibata 
N, Arai H, Kamboh MI, Prince JA, 
Maier W, Riemenschneider M, Owen 
M, Harold D, Hollingworth P, Cellini 
E, Sorbi S, Nacmias B, Takeda M, 
Pericak-Vance MA, Haines JL, Younkin 
S, Williams J, van Broeckhoven C, 
Farrer LA, St George-Hyslop PH, 
Mayeux R. Meta-analysis of the 
association between variants in SORL1 
and Alzheimer disease. Archives of 
Neurology. 2011;68:1, 99-106
[24] Reitz C, Tosto G, Vardarajan B, 
Rogaeva E, Ghani M, Rogers RS, 
Conrad C, Haines JL, Pericak-Vance 
11
A Molecular Mechanism for Abnormal Prion Protein Accumulation
MA, Fallin MD, Foroud T, Farrer LA, 
Schellenberg GD, George-Hyslop 
PS, Mayeux R. Independent and 
epistatic effects of variants in VPS10-d 
receptors on Alzheimer disease risk and 
processing of the amyloid precursor 
protein (APP). Translational Psychiatry. 
2013;3(5):e256-e256
[25] Hermey G. The Vps10p-domain 
receptor family. Cellular and Molecular 
Life Sciences. 2009;66(16):2677-2689
[26] Sarnataro D, Caputo A, Casanova 
P, Puri C, Paladino S, Tivodar SS, 
Campana V, Tacchetti C, Zurzolo 
C. Lipid rafts and clathrin cooperate in 
the internalization of PrP in epithelial 
FRT cells. PLoS One. 2009;4(6):e5829
[27] Nielsen MS, Madsen P, Christensen 
EI, Nykjær A, Gliemann J, Kasper 
D, Pohlmann R, Petersen CM. The 
sortilin cytoplasmic tail conveys 
Golgi-endosome transport and 
binds the VHS domain of the GGA2 
sorting protein. The EMBO Journal. 
2001;20(9):2180-2190
[28] Bonifacino JTL. Signals for 
sorting of transmembrane proteins 
for endosomes and lysosomes. 
Annual Review of Biochemistry. 
2003;72:395-447
[29] Sunyach C, Jen A, Deng J, 
Fitzgerald K, Frobert Y, Grassi J, 
Mccaffrey M, Morris R. The 
mechanism of internalisation of 
glycosylphosphatidylinositol-anchored 
prion protein. The EMBO Journal. 
2003;22(14):3591-3601
[30] Ren K, Gao C, Zhang J, Wang K, 
Xu Y, Bin Wang S, Wang H, Tian C, Shi 
Q, Dong XP. Flotillin-1 mediates PrPC 
endocytosis in the cultured cells during 
Cu2+ stimulation through molecular 
interaction. Molecular Neurobiology. 
2013;48(3):631-646
DOI: http://dx.doi.org/10.5772/intechopen.78951
